Robot-Assisted Lung Surgery After Immunotherapy for Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether combining immunotherapy with chemotherapy before robot-assisted lung surgery improves outcomes for patients with stage II–III non-small cell lung cancer. The goal is to shrink the tumor before surgery and then remove it completely using minimally invasive robotic techniques.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with confirmed lung cancer (non-small cell type)
- Cancer is stage IIB–III with no spread to other organs, and your doctors believe surgery is possible
- You are healthy enough for surgery (ECOG score 0–2, meaning you can do most daily activities)
- You will receive chemotherapy plus an immunotherapy drug (PD-1/PD-L1 inhibitor) before surgery—not chemotherapy alone
- You plan to have robot-assisted sleeve lobectomy (removal of part of lung and airways) with full lymph node removal
- You can complete 30 days of follow-up visits after surgery and provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with advanced non-small cell lung cancer (NSCLC) who receive combination chemotherapy and immunotherapy before surgery. Researchers will track how well surgery works after this pre-surgical treatment and compare different surgical approaches.
This trial tests a new combination of radiation, immunotherapy, and chemotherapy given before surgery for stage II or III lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial studies how well sleeve lobectomy (a type of lung-saving surgery) works for people with non-small cell lung cancer who have already received therapy like chemotherapy or immunotherapy before surgery. It aims to see if this approach is safe and effective.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a combination of three treatments given before surgery for lung cancer: targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib). The goal is to shrink the tumor and improve the chance of successful surgery.
Hear when a new Stage IIB-III NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.